St Vincent’s Hospital LUPIN Study PR, page-29

''It seems to me that Noxopharm is pursuing a well-thought-out strategy that is able to adapt if compelling information comes to light. A speculator might like to see spikes in the SP, but an investor likes to see solid development and blue sky potential. My view is that we have that in spades, in Noxopharm.''

IMO,

RBx in this high risk game imo an speculator and or investor would also want to sees spikes in SP

As good as NOX appears with all its pipeline drugs - long term success and investors- speculators making money is still very rare in this game

For me personally I review every announcement and make my next move accordingly

Been here since 2001 and have seen it all

DYOR